Asymptomatic Patients Received Repetitive HBOT Protocols to Evaluate Sustained Cardiac Effect TEL AVIV, Israel, Jan. 30, 2020 /PRNewswire/ — The Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center, one of the largest hyperbaric treatment centers in the world, today announced the results of a study that – for the first time in […]
Coronary/Structural Heart
CorMatrix® Cardiovascular, Inc. announces the first minimally invasive robotic implant of Cor® PATCH for epicardial support and repair
ATLANTA, Jan. 28, 2020 /PRNewswire/ — CorMatrix® Cardiovascular, Inc. www.cormatrix.com, a leading developer of regenerative cardiovascular medical devices, today announces the first minimally invasive robotic implant of Cor® PATCH by Dr. Husam H. Balkhy, Professor of Surgery, and Director of Robotic and Minimally Invasive Cardiac Surgery at the University of Chicago Medicine. Dr. Balkhy is a global leader […]
Neovasc Announces Executive Steering Committee for Transfemoral Trans-septal Tiara Program
VANCOUVER, Jan. 28, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today the Executive Steering Committee for […]
DalCor announces dal-GenE trial to continue as planned following interim futility analysis
LONDON and MONTREAL, Jan. 27, 2020 (GLOBE NEWSWIRE) — DalCor Pharmaceuticals today announced that following the results of the interim futility analysis of the dalcetrapib dal-GenE Phase 3 trial, DalCor will continue the dal-GenE trial as recommended by the independent Data and Safety Monitoring Board (DSMB). “We are pleased to […]
Neovasc Advances New Transfemoral Trans-septal Tiara Design Concept After Further Successful Tests
VANCOUVER, Jan. 24, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that after further successful acute […]
CHF Solutions Announces Launch of Aquapheresis Therapy Using Aquadex FlexFlow® System at the Baylor Scott & White Health System in Texas
EDEN PRAIRIE, Minn., Jan. 22, 2020 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS) today announced that Texas-based health system, Baylor Scott & White Health has initiated offering aquapheresis therapy using the company’s Aquadex FlexFlow® system at its Baylor Scott & White Medical Center in Temple, Texas. “Fluid overload continues to be […]
Renowned Cardiovascular Surgeons to Lead MemorialCare Heart & Vascular Institute, Offer Patients Least Invasive Heart Valve Surgery Breakthrough
ORANGE and LOS ANGELES Counties, Calif., Jan. 23, 2020 /PRNewswire/ — Nationally renowned cardiovascular surgeons Marc Sakwa, M.D. and Jeffrey Altshuler, M.D. are bringing their leadership, surgical advancements and world-class expertise in minimally invasive heart surgery for complex heart procedures to MemorialCare Heart & Vascular Institute, continuing the expansion and development of cardiovascular care services and the legacy […]
Teleflex Receives FDA Clearance for Wattson™ Temporary Pacing Guidewire
WAYNE, Pa., Jan. 22, 2020 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, today announced that it received 510(k) clearance from the U.S. Food and Drug Administration for the WattsonTM Temporary Pacing Guidewire – the first commercially available bipolar temporary […]
European Commission Grants BioVentrix CE Mark Extension for Revivent TC Less Invasive Ventricular Enhancement Therapy
SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, today announced the extension of its CE Mark for the Revivent TC™ Transcatheter Ventricular Enhancement System for heart failure to May 2024. “The extension of our CE Mark is not only an important […]
Ncardia and BlueRock Therapeutics Announce Collaboration Agreement and Licensing of Process Development Technologies for the Manufacture of iPSC-derived Cardiomyocytes
LEIDEN, the Netherlands & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Ncardia and BlueRock Therapeutics today announced an agreement covering process development technologies for the manufacture of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. Under the terms of the agreement, Bluerock gains access to Ncardia’s large-scale production processes and intellectual property for the production of iPSC-derived […]



